[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2854789T3 - Genotype- eller fænotype-baserede lægemiddelformuleringer - Google Patents

Genotype- eller fænotype-baserede lægemiddelformuleringer Download PDF

Info

Publication number
DK2854789T3
DK2854789T3 DK13725157.5T DK13725157T DK2854789T3 DK 2854789 T3 DK2854789 T3 DK 2854789T3 DK 13725157 T DK13725157 T DK 13725157T DK 2854789 T3 DK2854789 T3 DK 2854789T3
Authority
DK
Denmark
Prior art keywords
genotype
phenotype
pharmaceutical formulations
based pharmaceutical
formulations
Prior art date
Application number
DK13725157.5T
Other languages
English (en)
Inventor
Stefan Willmann
Kristin Dickschen
Thomas Eissing
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK2854789T3 publication Critical patent/DK2854789T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13725157.5T 2012-06-01 2013-05-27 Genotype- eller fænotype-baserede lægemiddelformuleringer DK2854789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
PCT/EP2013/060824 WO2013178565A1 (de) 2012-06-01 2013-05-27 Genotyp- bzw. phänotyp-basierte arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
DK2854789T3 true DK2854789T3 (da) 2019-09-16

Family

ID=48520964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725157.5T DK2854789T3 (da) 2012-06-01 2013-05-27 Genotype- eller fænotype-baserede lægemiddelformuleringer

Country Status (23)

Country Link
US (3) US10285958B2 (da)
EP (2) EP2668945A1 (da)
JP (2) JP6096289B2 (da)
KR (1) KR102129043B1 (da)
CN (2) CN104507464A (da)
AR (2) AR091234A1 (da)
AU (1) AU2013269793B2 (da)
BR (1) BR112014030059B1 (da)
CA (1) CA2875189C (da)
DK (1) DK2854789T3 (da)
ES (1) ES2744306T3 (da)
HK (1) HK1207296A1 (da)
HU (1) HUE045699T2 (da)
IL (1) IL235988B (da)
MX (1) MX370304B (da)
NZ (1) NZ702849A (da)
PL (1) PL2854789T3 (da)
PT (1) PT2854789T (da)
RU (1) RU2683260C2 (da)
SA (1) SA113340607B1 (da)
SG (2) SG10201610072UA (da)
TW (1) TWI644666B (da)
WO (1) WO2013178565A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
AU2001231091A1 (en) 2000-01-21 2001-07-31 Vincent P. Stanton Jr. Identification of genetic components of drug response
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
AU2004270150C1 (en) * 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
US7169813B2 (en) 2004-03-18 2007-01-30 Fondazione IRCCS “Istituto Nazionale Dei Tumori” 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
US7805282B2 (en) 2004-03-30 2010-09-28 New York University Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
WO2006130843A1 (en) * 2005-06-02 2006-12-07 Biovail Laboratories International S.R.L. Modified-release composition of at least one form of venlafaxine
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
EP1938231A1 (en) 2005-09-19 2008-07-02 BG Medicine, Inc. Correlation analysis of biological systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
IN2014MN00139A (da) 2006-11-21 2015-06-19 Jina Pharmaceuticals Inc
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
AU2009219228A1 (en) 2008-02-26 2009-09-03 Purdue Research Foundation Method for patient genotyping
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009137543A2 (en) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
MX366570B (es) 2008-06-30 2019-07-12 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
US20110136913A1 (en) * 2008-08-19 2011-06-09 Goetz Matthew P Assessing and treating breast cancer patients
WO2010036732A1 (en) 2008-09-25 2010-04-01 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
WO2010096834A2 (en) 2009-02-23 2010-08-26 Indiana University Research & Technology Corporation Materials and methods for treating patients with tamoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
NZ606903A (en) * 2010-08-26 2015-05-29 Ipca Lab Ltd Methods for the treatment or prophylaxis of thrombosis or embolism
KR20140047082A (ko) * 2011-06-27 2014-04-21 아이피시에이 래버러토리즈 리미티드 항-혈전 화합물
EA038600B1 (ru) 2012-04-02 2021-09-21 Берг Ллк Основанные на клетках перекрестные анализы и их применение
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
TW201400109A (zh) 2014-01-01
US10285958B2 (en) 2019-05-14
HUE045699T2 (hu) 2020-01-28
PL2854789T3 (pl) 2019-12-31
CN110075097A (zh) 2019-08-02
US20170326080A1 (en) 2017-11-16
IL235988A0 (en) 2015-01-29
WO2013178565A1 (de) 2013-12-05
AR091234A1 (es) 2015-01-21
HK1207296A1 (en) 2016-01-29
CN104507464A (zh) 2015-04-08
JP2015519350A (ja) 2015-07-09
MX2014014596A (es) 2015-03-03
AU2013269793B2 (en) 2018-03-01
NZ702849A (en) 2016-09-30
CA2875189A1 (en) 2013-12-05
ES2744306T3 (es) 2020-02-24
EP2854789B1 (de) 2019-06-26
RU2014154140A (ru) 2016-07-27
SG10201610072UA (en) 2017-01-27
BR112014030059B1 (pt) 2022-12-06
EP2854789A1 (de) 2015-04-08
KR20150022894A (ko) 2015-03-04
JP6096289B2 (ja) 2017-03-15
IL235988B (en) 2018-11-29
US20150174082A1 (en) 2015-06-25
CA2875189C (en) 2020-09-22
SA113340607B1 (ar) 2018-05-09
BR112014030059A2 (pt) 2017-07-25
PT2854789T (pt) 2019-09-18
KR102129043B1 (ko) 2020-07-01
SG11201407791VA (en) 2015-01-29
JP2017048234A (ja) 2017-03-09
AU2013269793A1 (en) 2015-01-22
US20170326081A1 (en) 2017-11-16
MX370304B (es) 2019-12-09
RU2683260C2 (ru) 2019-03-27
EP2668945A1 (de) 2013-12-04
AR118842A2 (es) 2021-11-03
TWI644666B (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
CY2022027I2 (el) Παραγωγα βενζιμιδαζολο-προλινης
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK3117837T3 (da) Antistofformuleringer
DK3725778T3 (da) Formuleringer af enzalutamid
BR112015006198A2 (pt) conjunto de cadeira
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
DK2864426T3 (da) Justerbare materialer
BR112015003160A2 (pt) corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos
GT201200303A (es) Formulaciones farmacéuticas
CO6930367A2 (es) Composiciones farmaceúticas
CO6940426A2 (es) Formulaciones farmacéuticas
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
DK2903896T3 (da) Baneindretning
DK2897594T3 (da) Farmaceutisk sammensætning
BR112014000015A2 (pt) formulação
DK2815752T3 (da) Oral farmaceutisk sammensætning
CL2014003283A1 (es) Formulación farmacéutica.
BR112014015885A2 (pt) preparação farmacêutica
FR2988426B1 (fr) Plate-forme inter-aubes
FR2988427B1 (fr) Plate-forme inter-aubes
CO7091176A2 (es) Diagnóstico farmacéutico
DK2931042T3 (da) Anthracyclinformuleringer
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
DK2672817T3 (da) Forbedrede insekticide formuleringer